ME
GoSymbol lookup
Health Care : Life Sciences Tools & Services | Company profile
23andMe Holding Co., formerly VG Acquisition Corp., is a consumer
genetics and research company.
The Company offers direct-to-consumer genetic testing and
personalized information about genetic health risks, ancestry,
and traits. The Company operates through two segments:
Consumer & Research Services and Therapeutics.
Its consumer & research services business segment comprises personal genome service (PGS) and research services.
Its PGS provides a suite of genetic reports,
including information on genetic ancestral origins,
personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses
to medications.
The Company’s therapeutics segment focuses on drug development
for discovering and developing therapies to improve patient lives
and includes out-licensing of intellectual property.
The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.
Recent ME News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:17:11 PM
- 23andMe Launches New Genetic Report on Bipolar Disorder • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community • GlobeNewswire Inc. • 06/04/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:06:02 PM
- 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:06:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 09:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:07:02 PM
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results • GlobeNewswire Inc. • 05/23/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:07:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:06:05 PM
- Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:06:05 PM
- 23andMe to Report Q4 and Full Year FY2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:50:07 PM
- Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case • Business Wire • 04/30/2024 03:00:00 PM
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:05:00 PM
- 23andMe announces CEO’s intention to pursue a potential take-private • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 04/05/2024 08:05:00 PM
- 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- 23andMe Launches New Genetic Reports on Common Forms of Cancer • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:36:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:07:48 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM